PDE3 isoforms play important roles in cAMP-mediated signaling in cardiac myocytes, and targeting these enzymes may improve the profile of clinical responses in patients with heart failure.
This review highlights the molecular biology of PDE3 isoforms in cardiac myocytes and their potential as therapeutic targets to improve clinical outcomes in heart failure.
Isoforms in the PDE3 family of cyclic nucleotide phosphodiesterases have important roles in cyclic nucleotide-mediated signalling in cardiac myocytes. These enzymes are targeted by inhibitors used to increase contractility in patients with heart failure, with a combination of beneficial and adverse effects on clinical outcomes. This review covers relevant aspects of the molecular biology of the isoforms that have been identified in cardiac myocytes; the roles of these enzymes in modulating cAMP-mediated signalling and the processes mediated thereby; and the potential for targeting these enzymes to improve the profile of clinical responses.
Movsesian et al. (Tue,) conducted a review in Heart failure. PDE3 inhibitors was evaluated. PDE3 isoforms play important roles in cAMP-mediated signaling in cardiac myocytes, and targeting these enzymes may improve the profile of clinical responses in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: